Display options
Cite
Franca CA, Vieira SL, Carvalho AC, et al. Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap. Radiol Bras. 2014;47(2):89-93doi: 10.1590/S0100-39842014000200010.
Franca, C. A., Vieira, S. L., Carvalho, A. C., Bernabe, A. J., & Penna, A. B. (2014). Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap. Radiologia brasileira, 47(2), 89-93. https://doi.org/10.1590/S0100-39842014000200010
Franca, Carlos Antônio da Silva, et al. "Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap." Radiologia brasileira vol. 47,2 (2014): 89-93. doi: https://doi.org/10.1590/S0100-39842014000200010
Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB. Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap. Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010. PMID: 25741055; PMCID: PMC4337165.
Copy Download .nbib Format: NLM
Share it on

Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010.

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap.

Radiologia brasileira

Carlos Antônio da Silva Franca, Sérgio Lannes Vieira, Antonio Carlos Pires Carvalho, Antonio Jose Serrano Bernabe, Antonio Belmiro Rodrigues Campbell Penna

Affiliations

  1. Master, MD, Radiation Oncology at Instituto Brasileiro de Oncologia (IBO), Radioterapia Botafogo, Universidade Federal do Rio de Janeiro (UFRJ) and Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.
  2. Full Professor, MD, Radiation Oncology at Instituto Brasileiro de Oncologia (IBO), Radioterapia Botafogo and Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.
  3. PhD, Professor at Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  4. MD, Urologist at Radioterapia Botafogo, Rio de Janeiro, RJ, Brazil.
  5. PhD, MD, Radiation Oncology at Instituto Brasileiro de Oncologia (IBO), Radioterapia Botafogo and Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.

PMID: 25741055 PMCID: PMC4337165 DOI: 10.1590/S0100-39842014000200010

Abstract

OBJECTIVE: To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients.

MATERIALS AND METHODS: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus.

RESULTS: Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively.

CONCLUSION: Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.

Keywords: Brachytherapy; Iodine radioisotopes; PSA nadir; Prostatic neoplasms

References

  1. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99 - PubMed
  2. Urology. 2012 Sep;80(3):649-55 - PubMed
  3. J Clin Oncol. 2012 May 20;30(15):1857-63 - PubMed
  4. Radiat Oncol. 2013 Mar 13;8:58 - PubMed
  5. Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):73-7 - PubMed
  7. Cancer. 2012 Apr 15;118(8):2059-68 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1350-6 - PubMed
  9. Brachytherapy. 2007 Jan-Mar;6(1):9-15 - PubMed
  10. Urology. 1999 Dec;54(6):968-71 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):57-64 - PubMed
  12. Cancer. 1997 Aug 1;80(3):442-53 - PubMed
  13. J Urol. 2004 Mar;171(3):1132-6 - PubMed
  14. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):384-90 - PubMed
  15. Cancer. 2005 Jun 15;103(12):2499-506 - PubMed
  16. J Am Coll Radiol. 2012 Apr;9(4):233-8 - PubMed
  17. J Urol. 1996 Aug;156(2 Pt 1):450-3 - PubMed
  18. J Urol. 2012 Jun;187(6):2068-73 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 - PubMed
  20. Urology. 2003 Sep;62(3):492-6 - PubMed
  21. Radiother Oncol. 2010 Jul;96(1):25-9 - PubMed
  22. Brachytherapy. 2010 Oct-Dec;9(4):307-12 - PubMed
  23. Radiother Oncol. 2006 Jan;78(1):47-52 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33 - PubMed
  25. Int Braz J Urol. 2007 Nov-Dec;33(6):752-62; discussion 762-3 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92 - PubMed
  27. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303 - PubMed
  28. Cancer. 2013 Jun 1;119(11):1999-2004 - PubMed

Publication Types